All In Biotech

Free tool

FAERS Monitor: Icotyde

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220149 or its brand name (Icotyde, Icotrokinra Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

428

Serious

66

15% of reports

Hospitalization

15

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache46
  • nausea38
  • product dose omission issue30
  • fatigue27
  • rash24
  • drug ineffective23
  • psoriasis19
  • off label use15
  • pain15
  • diarrhoea14
  • cough13
  • abdominal discomfort12
  • pruritus12
  • gastrointestinal disorder9
  • arthralgia8

Reports by year received

View as table
YearReports
2026428

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,731 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal197.14.695
product dose omission issueSignal305.03.694
gastrointestinal disorderSignal94.92.625
headacheSignal463.62.787
abdominal discomfortSignal123.52.019
rashSignal242.71.825
nauseaSignal382.41.730
coughSignal132.31.38
fatigue271.71.27
pruritus121.50.92
pain151.20.70
diarrhoea141.10.60
arthralgia80.90.50
drug ineffective230.90.60
off label use150.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.